比奇珠单抗(Bimekizumab) - 药物靶点：IL-17A x IL-17F_在研适应症：化脓性汗腺炎，强直性脊柱炎，中轴性脊柱关节炎_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Anti-IL-17-mAb-UCB、Anti-IL-17-monoclonal-antibody-UCB、Anti-interleukin-17-monoclonal-antibody-UCB

+ [14]

靶点

IL-17A x IL-17F

作用方式

抑制剂

作用机制

IL-17A抑制剂(白细胞介素-17A抑制剂)、IL-17F抑制剂(白介素-17F抑制剂)

治疗领域

免疫系统疾病感染皮肤和肌肉骨骼疾病+ [1]

在研适应症

化脓性汗腺炎强直性脊柱炎中轴性脊柱关节炎+ [9]

非在研适应症

流感病毒感染类风湿关节炎

原研机构

UCB SA

在研机构

UCB Pharma SAUCB Biopharma SRL

UCB, Inc.

+ [6]

非在研机构

UCB Celltech

最高研发阶段批准上市

首次获批日期

欧盟 (2021-08-20),

银屑病关节炎斑块状银屑病

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 9975662H

来源: *****

Sequence Code 13372170L

来源: *****

关联

59

项与比奇珠单抗相关的临床试验

NCT06888193

/ Not yet recruiting临床1期

A Multicenter Open-label, Prospective Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.

开始日期2025-04-07

申办/合作机构

UCB Biopharma SRL

NCT06742333

/ Not yet recruiting临床2期IIT

Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation? Prospective Multicenter Interventional Study

Psoriasis is a chronic inflammatory condition driven by a complex interplay between heritable and microenvironmental factors. Genome-wide heritability for psoriasis (PsO) is estimated at up to 50%. Although bearing genetic susceptibility at birth, most patients will remain disease free for years until an exposomal trigger activates the immunological pathway that leads to the first disease flare. In rare patients, the first flare is an isolated event, but in most patients it will evolve into a chronically relapsing-remitting disease characterized by lasting lesions and recurrent flares. Primary objective is to compare efficacy of bimekizumab versus topical corticosteroids on psoriasis clinical disease activity, assessed by PGA, at week 16 and week 24.
Patients will be randomized 1:1 to receive either 320mg bimekizumab at weeks 0 (W0), W4, W8 and W12, or clobetasol ointment for 2 to 4 weeks until complete clearance of the lesion. After a maximum of 4 weeks topical clobetasol will be applied twice weekly on the site of lesion until week 16 then stopped. Patients will not receive active treatment between week 16-24. Between week 24-96 patients that flare can receive continuous topical clobetasol if needed. These patients will be considered non-responders at subsequent timepoints for the main analysis. If the patients worsen their psoriasis under the treatments given during the study and progress to moderate or severe psoriasis (PASI 10 and above) they will end their participation to the study to receive a treatment adapted to the new severity of their psoriasis. The patients will be referred to their dermatologist to receive the actual standard of care adapted to their new condition.
During the study, the following assessments will be performed and samples will be collected

开始日期2025-04-01

申办/合作机构

Centre Hospitalier Universitaire de Nice

NCT06668181

/ Recruiting临床3期

Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants From 2 to Less Than 18 Years of Age With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-Related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.

开始日期2025-03-11

申办/合作机构

UCB Biopharma SRL

100 项与比奇珠单抗相关的临床结果

登录后查看更多信息

100 项与比奇珠单抗相关的转化医学

登录后查看更多信息

100 项与比奇珠单抗相关的专利（医药）

登录后查看更多信息

283

项与比奇珠单抗相关的文献（医药）

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics

Article

作者: Bianchi, L. ; Loconsole, F. ; Gaeta Shumak, R. ; Mortato, E. ; Rivieccio, Antonia ; Campione, E. ; Lanna, C. ; Borselli, C. ; Artosi, F. ; Lambiase, S. ; Compagnucci, I.

PURPOSE:

Psoriasis is a chronic, immune-mediated inflammatory skin condition marked by erythematous, scaly plaques. This retrospective observational study evaluated the long-term efficacy and safety of bimekizumab, a dual IL-17A and IL-17F inhibitor, in treating moderate to severe plaque psoriasis in 56 patients across two dermatology clinics in Italy.

MATERIALS AND METHODS:

Adult participants with a baseline Psoriasis Area and Severity Index (PASI) >10, or <10 with sensitive area involvement, were followed for 16 to 52 weeks. Clinical outcomes were measured by PASI 75, 90, and 100 responses and Dermatology Life Quality Index (DLQI) scores at 4, 16, 36, and 52 weeks.

RESULTS:

At week 16, 97.5% of patients achieved PASI 75, 76.7% reached PASI 90, and 66% attained PASI 100. By week 52, 91.5% achieved PASI 90 and 85.1% reached PASI 100, with 95.7% reporting a Dermatology Life Quality Index (DLQI) score of 0 or 1, indicating minimal impact on daily life. The study found similar efficacy across bio-naïve and bio-experienced groups, and between normal-weight and obese patients, without statistically significant differences. The safety profile was consistent with previous trials, with oral candidiasis as the most frequent adverse event (21%).

CONCLUSIONS:

These findings support the efficacy and tolerability of bimekizumab for long-term psoriasis management.

2025-03-18·BRITISH JOURNAL OF DERMATOLOGY

The roles of interleukin (IL)-17A and IL-17F in hidradenitis suppurativa pathogenesis: evidence from human in vitro preclinical experiments and clinical samples

Article

作者: Page, Matthew ; Shaw, Stevan ; Edwards, Hannah ; Rastrick, Joseph ; Le Friec, Gaëlle ; Manghera, Avneet ; Ferecskó, Alex S

Abstract:

Background:

Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory skin disease associated with significant comorbidities and poor quality of life. Despite uncertainty about pathways driving inflammation in HS lesions, the cytokines interleukin (IL)-17A and IL-17F have been shown to be upregulated in patients with HS. Previous studies have demonstrated that the monoclonal IgG1 antibody bimekizumab selectively inhibits IL-17F in addition to IL-17A.

Objectives:

To further investigate the roles of IL-17A and IL-17F in HS pathogenesis.

Methods:

RNA sequencing (RNAseq) was conducted on skin biopsies taken at baseline and after treatment at week 12 of a phase II proof-of-concept study of bimekizumab in patients with moderate-to-severe HS. Differentially expressed genes were identified between baseline lesional and nonlesional samples and between lesional samples before and after bimekizumab treatment, to describe molecular disease mechanisms and treatment effect. Human hair follicular keratinocytes (HHFK) were cultured and treated with a supernatant of stimulated T helper (Th)17 cells in combination with anti-IL-17A, anti-IL-17F, anti-IL-17A and anti-IL-17F, or IgG control antibodies. Total mRNA was analysed by RNAseq. Cellular supernatants from the stimulated HHFKs were used as a source of Th17-induced chemoattractants in neutrophil chemotaxis assays.

Results:

RNAseq revealed that the most prominently upregulated genes in HS lesions included those associated with neutrophil biology. Bimekizumab treatment resulted in reduced expression of these genes. The extent of reduction in gene expression was dependent on achieving HiSCR50 (≥ 50% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count). In vitro dual inhibition of IL-17A and IL-17F had greater attenuation of Th17-induced HS-associated genes and neutrophil migration in HHFKs vs. IL-17A or IL-17F inhibition alone. In situ hybridization found that IL-17A- and IL-17F-producing cells in HS lesions can lack the IL-23 receptor and IL-1β could induce IL-23-independent IL-17F expression in vitro. Furthermore, mucosal-associated invariant cells in HS tunnels expressed IL-17F and IL-1 receptor type 1. IL-1β-, IL-17A- and IL-17F-expressing cells were found to be co-localized in HS lesions.

Conclusions:

These data support the hypothesis that IL-17A and IL-17F play central roles in HS, a neutrophilic dermatosis. The presence of IL-1β may partly explain the high expression of IL-17F in lesional HS tissue.

2025-03-01·JOURNAL OF DERMATOLOGY

Effective management of coexisting bullous pemphigoid and psoriasis with bimekizumab

Letter

作者: Suzuki, Tamio ; Suto, Hajime ; Arai, Yosuke ; Okamura, Ken ; Saito, Toru

227

项与比奇珠单抗相关的新闻（医药）

2025-03-25

·Endpoints

Another immunology biotech emerges as Hillstar takes flight with $67M

The flurry of immunology biotech launches continues. Boston-based Hillstar Bio on Tuesday became the latest immunology startup launch, unveiling a $67 million Series A round funded by Droia Ventures, Frazier Life Sciences, Novo Holdings and LifeArc Ventures. The biologics developer has been in the works since 2023, CEO Robert Mabry told Endpoints News . Mabry joined Hillstar in recent months after departing his chief scientific officer post at RNA medicines outfit Orna Therapeutics . “It’s just such a fantastic time for biologics right now. You’re seeing just a renaissance. All the technology is coming to fruition,” Mabry said. With the Series A, Hillstar expects to get into the clinic next year with its first biologic. The startup will begin in axial spondyloarthritis, or axSpA. The inflammatory condition leads to lower back pain, causing arthritis in the spine and other joints and organs. Approved medicines for the condition include Novartis’ Cosentyx, UCB’s Bimzelx and AbbVie’s Rinvoq . Others, like Acelyrin, once had ambitions in the space. Hillstar’s HSB-101 biologic targets TRBV9 + T cells. The goal is to invoke an “immune reset,” Mabry said. Beyond its lead asset, Hillstar could go into cold agglutinin disease, or CAD, according to a job posting for the company. In the rare condition, a patient’s immune system prematurely kills red blood cells. Sanofi sold Enjaymo, its approved drug for the condition, to Recordati for $825 million in October. “It’s still an area that we’re exploring,” Mabry said of CAD. “What we’ve been able to generate is a proprietary dataset using patient samples in that area, so we’re very excited about that as one of many different autoimmune diseases that we can go after.” Leading the biotech’s development is former Boston Pharmaceuticals clinical development SVP Mitchell Keegan. Hillstar’s chief operating officer is Lauren Mifflin, a principal of company creation at one of the startup’s key investors, Frazier Life Sciences. Hillstar’s board includes Mabry, Ingram, Novo Holdings senior partner Kenneth Harrison, Frazier General Partner Dan Estes, Droia Managing Partner Luc Dochez and Droia Partner Matthias Van Woensel. Mabry emphasized that the startup is an asset-focused company with drugs near the clinic — a profile investors have favored over the last few years of a moribund biotech sector. “We’re an asset company, a pipeline company — we’re not a platform technology company,” Mabry said. “That really changes the way you can run a biotech company. It changes the way you use the capital.” Along with the investment funds, another key Hillstar backer is Hummingbird Bioscience, a Singapore-based biotech that originated about a decade ago and that has antibody and antibody-drug conjugate platforms. Earlier this month, Frazier and Novo Holdings backed an ADC spinout from Hummingbird called Callio Therapeutics . “They’ve been a great shareholder for us and so being able to leverage them as part of our development, but also gaining access to other technologies that provide a lot of insight into development, that’s been a great partnership for us,” Mabry said of Hummingbird.

上市批准免疫疗法

2025-03-17

·FierceBiotech

Incyte posts phase 3 skin condition wins but details disappoint, sinking stock

While Incyte called the data positive, investors were unconvinced and sent the biotech’s share price down.\n Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo-adjusted response rate down on phase 2, the results drew unfavorable comparisons to rival data and triggered a 15% drop in the biotech’s share price. The JAK1 inhibitor, povorcitinib, could offer an oral alternative to biologics in multiple indications and, if approved, partly offset the loss of exclusivity of Incyte\'s JAKi Jakafi later this decade. Incyte took the candidate into phase 3 trials in the skin condition hidradenitis suppurativa (HS) after seeing (PDF) placebo-adjusted response rates of up to 27.7% in a mid-stage study. Asked by analysts at recent investor events, Incyte executives declined to name the number they were targeting in the phase 3 trials but did say they expected to see a profile that is consistent with the earlier trial. The primary endpoints looked at the number of patients who had a 50% or greater reduction in total abscess and inflammatory nodule count with no increase in abscess or draining tunnel count. In the first study, around 40% of patients on both the low and high dose met the criteria, versus around 30% on placebo. The drug and placebo figures in the second trial were around 42% and 29%, respectively. Adjusted for placebo, the response rates at the low and high dose were 10.5% and 10.9%, respectively, in the first trial. The figure for both doses was 13.7% in the second trial. In the earlier phase 2 trial, Incyte reported placebo-adjusted results of 17.3% and 27.7%, respectively, at the low and high doses used in the pivotal studies. Incyte saw higher placebo-adjusted results in a predefined subgroup of phase 3 patients who previously took a biologic. The biotech also found more people on povorcitinib had a 75% or greater improvement, experienced a reduction in flares and reported a more than three-point improvement on a pain scale. The overall safety profile of povorcitinib was consistent with previous data, according to Incyte.While the biopharma called the data positive, investors were unconvinced and sent the biotech’s share price down around 15% to just $58 in early premarket trading. The drop may reflect unfavorable comparisons between the phase 3 data and both Incyte’s midphase results and the evidence on rival biologics. UCB won approval for Bimzelx in HS after linking the biologic to placebo-adjusted response rates of 19% and 20% after 16 weeks in two phase 3 trials. Novartis’ biologic Cosentyx is also approved in the indication. Povorcitinib has the advantage of oral administration but the data leave scope to question the size of the opportunity that will be open to the small molecule.

临床结果临床3期临床2期上市批准

2025-03-17

·Endpoints

Incyte's stock sinks as pivotal skin disease data disappoint

Incyte’s topline pivotal data for its oral therapy for a painful inflammatory skin condition appear somewhat disappointing, with efficacy falling short of analysts’ expectations and in comparison with marketed drugs like UCB’s Bimzelx. The company’s shares $INCY fell about 10% on Monday morning. Incyte said Monday that the STOP-HS1 and STOP-HS2 studies of povorcitinib met their primary endpoints in patients with moderate-to-severe hidradenitis suppurativa (HS). After three months of treatment, significantly more patients given the JAK1 inhibitor than those given placebo had a reduction of at least 50% in the number of abscesses and inflammatory nodules, with no increase in abscess or draining tunnel count. This measure is known as HiSCR50. But the improvements over placebo were not as extensive as some had hoped. With the lower dose of povorcitinib — 45 mg once daily — the HiSCR50 delta was 10.5 percentage points in STOP-HS1 and 13.7 points in STOP-HS2. The differences versus placebo seen with the higher dose — 75 mg per day — were almost identical. That’s an odd finding, since a higher dose would be expected to work better. “We’ll have to wait for longer-term follow-up to see if there’s a separation of the 45 and 75 [mg doses],” Incyte head of R&D Pablo Cagnoni said during an analyst call to discuss the data. He added that Incyte plans to provide more data on this point later this year. Incyte also said the drug’s efficacy was better in patients who had previously been treated with biologics. Here the deltas over placebo were larger, but the p-value for the difference between the 45 mg dose and placebo in the HS-1 trial was 0.096, missing the generally accepted threshold for significance. William Blair analysts pointed out that the data came in well below the Phase 2 results, which showed placebo-adjusted HiSCR50 response rates of 18 to 28 percentage points. They added that even on an absolute basis, the Phase 3 HiSCR50 response rates for povorcitinib were markedly lesser than those seen in Phase 2. Incyte intends to wait for further data from the trial before seeking approval for the pill, and it’s aiming for an NDA submission at the end of this year or early next year. The Phase 3 data might be good enough for approval, with Incyte saying on the call that it believes regulators will greenlight povorcitinib for both biologic-naïve and -experienced patients. But doctors might have little reason to prescribe the pill when several approved injected drugs still look more effective. For example, in the pivotal HS trials for Bimzelx, the HiSCR50 delta was 19 to 26 percentage points. This was after four weeks of treatment, which is slightly longer than Incyte’s STOP-HS1 and STOP-HS2 trials, but the effect size is much greater. Another competitor is not far behind. There are high expectations for the pivotal data on MoonLake Immunotherapeutics’ antibody sonelokimab in HS. Those data should be revealed in the third quarter of this year.

临床结果临床3期临床2期免疫疗法

100 项与比奇珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11550	比奇珠单抗	-	DB12917

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
化脓性汗腺炎	欧盟	UCB Pharma SA	2024-04-30
化脓性汗腺炎	冰岛	UCB Pharma SA	2024-04-30
化脓性汗腺炎	列支敦士登	UCB Pharma SA	2024-04-30
化脓性汗腺炎	挪威	UCB Pharma SA	2024-04-30
强直性脊柱炎	欧盟	UCB Pharma SA	2023-06-15
强直性脊柱炎	冰岛	UCB Pharma SA	2023-06-15
强直性脊柱炎	列支敦士登	UCB Pharma SA	2023-06-15
强直性脊柱炎	挪威	UCB Pharma SA	2023-06-15
中轴性脊柱关节炎	欧盟	UCB Pharma SA	2023-06-15
中轴性脊柱关节炎	冰岛	UCB Pharma SA	2023-06-15
中轴性脊柱关节炎	列支敦士登	UCB Pharma SA	2023-06-15
中轴性脊柱关节炎	挪威	UCB Pharma SA	2023-06-15
非放射性轴性脊柱关节炎	欧盟	UCB Pharma SA	2023-06-15
非放射性轴性脊柱关节炎	冰岛	UCB Pharma SA	2023-06-15
非放射性轴性脊柱关节炎	列支敦士登	UCB Pharma SA	2023-06-15
非放射性轴性脊柱关节炎	挪威	UCB Pharma SA	2023-06-15
红皮病性银屑病	日本	UCB Japan Co. Ltd.	2022-01-20
寻常性银屑病	日本	UCB Japan Co. Ltd.	2022-01-20
脓疱型银屑病	日本	UCB Japan Co. Ltd.	2022-01-20
银屑病关节炎	欧盟	UCB Pharma SA	2021-08-20

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
附着点炎相关关节炎	临床3期	加拿大	UCB Biopharma SRL	2025-03-11
附着点炎相关关节炎	临床3期	法国	UCB Biopharma SRL	2025-03-11
附着点炎相关关节炎	临床3期	波兰	UCB Biopharma SRL	2025-03-11
幼年特发性关节炎	临床3期	加拿大	UCB Biopharma SRL	2025-03-11
幼年特发性关节炎	临床3期	法国	UCB Biopharma SRL	2025-03-11
幼年特发性关节炎	临床3期	波兰	UCB Biopharma SRL	2025-03-11
慢性大斑块银屑病	临床3期	美国	UCB Biopharma SRL	2018-06-13
慢性大斑块银屑病	临床3期	澳大利亚	UCB Biopharma SRL	2018-06-13
慢性大斑块银屑病	临床3期	比利时	UCB Biopharma SRL	2018-06-13
慢性大斑块银屑病	临床3期	加拿大	UCB Biopharma SRL	2018-06-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04242446 (BE HEARD I, CTgov)	临床3期	化脓性汗腺炎	505	placebo (Placebo)	壓蓋鹽鬱壓鏇鏇選餘膚 = 簾製繭繭蓋築遞遞憲衊壓鬱蓋窪蓋憲襯鬱醖壓 (願襯齋壓糧餘鹽構鑰鏇, 選鹽鹽糧繭鹹鏇範鹽糧 ~ 築廠積鑰觸顧觸構壓鏇) 更多	-	2025-03-25
				BKZ (BKZ Dosing Regimen 1)	壓蓋鹽鬱壓鏇鏇選餘膚 = 構獵鹽醖鹽鬱壓選蓋憲壓鬱蓋窪蓋憲襯鬱醖壓 (願襯齋壓糧餘鹽構鑰鏇, 糧網蓋蓋襯簾網顧淵顧 ~ 糧鹹窪壓鑰憲獵製夢願) 更多
BE AGILE (Pubmed \| RMD Open)	临床2期	强直性脊柱炎 \| 中轴性脊柱关节炎	-	Bimekizumab 160 mg every 4 weeks	願構遞蓋壓顧選製鏇獵(鬱醖範襯鹽餘齋範繭衊) = 膚艱齋醖夢鏇構醖淵鏇鏇衊餘夢網鬱糧獵膚顧 (網顧鹹膚簾鹽獵衊鏇願 ) 更多	积极	2025-01-01
NCT03598790 (BE BRIGHT, CTgov)	临床3期	斑块状银屑病	1,353	BKZ (Cohort A: BKZ 320 mg Q8W)	憲積觸製襯艱顧廠範築 = 餘憲餘廠觸鹹觸膚蓋蓋鹽窪構憲鹽網鑰築網襯 (艱鹽鏇簾網鏇獵簾膚構, 鏇繭簾範願廠積餘齋衊 ~ 衊淵壓顧獵築糧衊糧艱) 更多	-	2024-12-06
				BKZ (Cohort A: BKZ 320 mg Q4W)	憲積觸製襯艱顧廠範築 = 膚鑰鏇齋餘壓鹽糧獵膚鹽窪構憲鹽網鑰築網襯 (艱鹽鏇簾網鏇獵簾膚構, 壓蓋範蓋窪壓壓糧獵繭 ~ 鬱鑰蓋遞遞願鏇膚網積) 更多
NCT04242498 (BE HEARD II, CTgov)	临床3期	化脓性汗腺炎	509	placebo (Placebo)	積糧鬱構壓糧憲積餘醖 = 範觸淵襯糧膚淵鹹鬱艱鬱廠糧糧遞憲觸獵願鏇 (蓋選網醖網顧築鏇餘鬱, 製淵鬱選鏇醖膚窪鬱範 ~ 膚糧衊醖壓鏇範築餘築) 更多	-	2024-12-05
				BKZ (BKZ Dosing Regimen 1)	積糧鬱構壓糧憲積餘醖 = 鑰膚選鬱淵選廠顧範網鬱廠糧糧遞憲觸獵願鏇 (蓋選網醖網顧築鏇餘鬱, 獵繭鬱網願構獵顧艱鬱 ~ 簾顧獵構觸襯窪窪遞簾) 更多
Pubmed \| Ann Rheum Dis	N/A	中轴性脊柱关节炎	-	Bimekizumab 160 mg	廠繭蓋餘廠製艱範鑰製(膚鹹選淵範衊獵齋構憲) = 遞夢築艱簾顧簾鬱憲夢繭糧構齋積遞齋觸壓積 (觸襯鹽積獵鏇衊膚鹹餘 )	-	2024-12-01
				Placebo	廠繭蓋餘廠製艱範鑰製(膚鹹選淵範衊獵齋構憲) = 糧糧廠鬱繭糧蓋網構構繭糧構齋積遞齋觸壓積 (觸襯鹽積獵鏇衊膚鹹餘 )
NCT03412747 \| NCT03370133 \| NCT03536884 \| NCT03410992 \| NCT03598790 (BE VIVID \| BE READY \| BE SURE \| BE BRIGHT \| BE RADIANT, Pubmed \| Dermatol Ther (Heidelb))	临床3期	银屑病	1,107	Bimekizumab	膚鬱齋觸廠鏇廠壓遞繭(築構淵糧構壓齋構願鹽) = 廠壓繭鹽簾壓齋糧築選餘遞壓艱衊簾製糧襯鑰 (衊艱衊壓築淵糧鹽鏇鹹 ) 更多	积极	2024-12-01
NCT03928704 (BE MOBILE 1, CTgov)	临床3期	非放射性轴性脊柱关节炎	274	Placebo (Placebo (up to Week 16) (Global Population))	築鑰繭餘積遞簾夢鏇艱 = 壓獵襯糧鏇築願簾憲願襯窪憲積淵範遞顧簾鑰 (糧選鹹獵鏇遞網鬱顧網, 鹽糧鑰顧憲顧衊簾鑰鑰 ~ 糧願遞積窪鬱鹽淵淵醖) 更多	-	2024-11-13
				Bimekizumab (Bimekizumab 160 mg Q4W (up to Week 16) (Global Population))	築鑰繭餘積遞簾夢鏇艱 = 製選憲襯願積餘顧鏇膚襯窪憲積淵範遞顧簾鑰 (糧選鹹獵鏇遞網鬱顧網, 顧淵淵簾選構選鑰簾簾 ~ 鏇淵簾繭淵衊醖觸壓餘) 更多
NCT03355573 (BE AGILE \| OLE \| BE AGILE 2, CTgov)	临床2期	强直性脊柱炎	255	Bimekizumab	選網膚衊繭積鏇製膚蓋 = 廠鏇繭獵廠選鑰窪壓壓遞蓋範餘顧艱廠構範廠 (夢鑰醖窪鏇繭鹽鏇獵廠, 築夢鏇糧網願繭鹹鑰襯 ~ 鏇醖淵獵鑰淵壓構願窪) 更多	-	2024-11-13
NCT03895203 (BE OPTIMAL, CTgov)	临床3期	银屑病关节炎	852	Placebo+Bimekizumab	廠遞選糧鹽壓鑰製築遞 = 醖齋顧網鏇積築蓋襯繭膚壓淵壓獵醖糧範鹽製 (艱餘鬱夢範顧艱選網壓, 製艱膚夢壓壓鬱膚繭鏇 ~ 築構膚憲願淵艱齋蓋鏇) 更多	-	2024-10-23
NCT03896581 (BE COMPLETE, CTgov)	临床3期	银屑病关节炎	400	Placebo	構憲鬱簾積糧壓簾憲選 = 築醖夢鬱廠遞顧襯膚範鏇艱憲鹹鏇蓋顧艱艱廠 (糧鬱觸艱窪齋觸膚範蓋, 觸鑰餘鏇築齋願願願鹹 ~ 鏇遞鹽衊齋願襯獵窪獵) 更多	-	2024-10-16